Navigation Links
Hyperion Therapeutics Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of GT4P in Patients With Urea Cycle Disorders
Date:10/23/2007

d synthetase (AS)), and a pre-prodrug of phenylacetate (PAA).

About Urea Cycle Disorder

A urea cycle disorder is an inherited, inborn error of metabolism present in an estimated 1 in 10,000 live births in the U.S. Patients with UCDs lack or are deficient in one of the key enzymes that comprise the urea cycle, the body's primary vehicle for removing ammonia, a potent neurotoxin, from the bloodstream. The age of onset of UCDs is typically in the neonatal period, but onset can occur at any age, depending on the severity of the disorder. Left untreated, UCDs can cause dangerously heightened levels of ammonia in the bloodstream (hyperammonemia) resulting in brain damage, coma, and/or death.

There is no cure for UCDs. Adherence to a low-protein diet is a key component to chronic disease management. Current therapies include arginine supplementation, which drives functional parts of the urea cycle, essential amino acid supplementation, replacement of urea cycle intermediates, and administration of nitrogen-scavenging drugs including BUPHENYL(R) for chronic management and AMMONUL(R) (sodium phenylacetate and sodium benzoate) disease Injection 10%/10% for episodes of acute hyperammonemia. Orthotopic liver transplantation may also be considered for patients with severe disease.

About Hyperion Therapeutics

Hyperion Therapeutics is a specialty therapeutics company focused on becoming a global leader in gastrointestinal (GI) and hepatology therapeutic programs and products that address underserved patient populations or unmet medical needs. The company has assembled a seasoned executive team with extensive industry experience developing and commercializing specialty pharmaceutical products. Hyperion is headquartered in South San Francisco, CA. For additional information, visit: http://www.hyperiontx.com.

About AMMONUL(R)

AMMONUL(R) is indicated as adjunctive therapy for the treatment
'/>"/>

SOURCE Hyperion Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- Encision Inc. (PK:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of ... thousand, or $(0.02) per share. These results compare to ... of $202 thousand, or $(0.02) per share, in the ...
(Date:8/3/2015)... 2015  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ; ... exclusive licensing agreement to develop and commercialize multiple prespecified ... a holding company for premier antibody development and manufacturing ... Under the terms of the agreement, Sorrento will ... the North American, European and Japanese market. Each of ...
(Date:8/2/2015)... Aug. 3, 2015  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... TELESTAR Phase 3 clinical trial met its primary ... in treating cancer patients with carcinoid syndrome that ... of care. Telotristat etiprate was discovered using Lexicon,s ... is the company,s first discovery to complete a ...
Breaking Medicine Technology:Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 2Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6
... 9, 2012  The National Association of Drug ... facilitates cooperation between law enforcement, healthcare professionals, ... the prevention and investigation of drug diversion -- ... Log Exchange (NPLEx) in Kentucky is blocking ...
... MedPlast, Inc.,s ability to craft the pessary balloons ... the company,s commitment to premium quality output and complete ... Today,s pessaries are precision-manufactured medical devices that ... treat a variety of gynecologic conditions, including prolapse. In ...
Cached Medicine Technology:Kentucky Real-Time, Stop-Sale System Is Effective In Blocking Illegal Sales Of Pseudoephedrine 2MedPlast's Pessary Balloon Manufacture Showcases Multi-Function Technical Mastery 2
(Date:8/3/2015)... , ... August 03, 2015 , ... Dignity Health named ... Arizona General Hospital Emergency Room – Gilbert, opening in August. The new facility ... year in the West Valley. , “Dr. Baldwin is an excellent leader and ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... of medical information, risk management and investigative services, has introduced a new ... focused, expert information solutions that improve business outcomes for its customers. EMSI’s ...
(Date:8/2/2015)... ... ... A new Phase I research study is looking at a vaccine that hopes ... G. Lucas, M.D. , chief of the division of pediatric hematology/oncology and stem cell ... Hospital and in the UofL Department of Pediatrics . Patients are currently ...
(Date:8/1/2015)... ... 02, 2015 , ... Back packs can be dangerous? Whaaat?! , Not the ... wreck havoc on a kid's spine. With school starting again, most kids will be ... sure you are aware of how to help them prevent injuries by understanding backpack ...
(Date:8/1/2015)... ... August 01, 2015 , ... Tina Wilcoxson, owner of Freeport Maine’s Royal ... that honor by the National Retail Federation, the largest retail trade association in the ... three Maine business owners to be named as such. According to the NRF’s website, ...
Breaking Medicine News(10 mins):Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Local Retail Advocate Wins National Recognition 2
... Meet Isabel, a busy,active 50-year-old Hispanic woman who has ... son; and enjoys being a grandmother to her,daughter,s son. ... her wrist, and her doctor tells her she has ... is typical of many women like her. To ...
... Mobile Dental Clinic to Visit Delaware,Philadelphia, and Southern New Jersey ... to Area Children ... The St. Christopher,s,Foundation for Children Ronald McDonald Care Mobile ... Dental Hygiene Month,(October). The tour will include stops at the ...
... for Pulmonary Study, SOLANA BEACH, Calif., ... a firm specializing in patient recruitment for,clinical ... of Regional Recruitment,Specialists(TM) in support of recruiting ... Pulmonary Disease (COPD) for a recently initiated,clinical ...
... WASHINGTON, Oct. 1 House Republican Whip Roy,Blunt (Mo.) ... posturing and work with Republicans on crafting a real,meaningful ... to quality health care., "If Democrats are serious ... they,ll have to start working with House,Republicans to craft ...
... at ERS 17th Annual Congress -, REDWOOD ... announced the submission of a pre-market approval (PMA) ... requesting regulatory,approval to market the Emphasys endobronchial valve, ... EBV is a minimally invasive and potentially,reversible treatment ...
... Del., Oct. 1 More than 125 leaders,from ... Ann Minner, joined,together to support a multi-year, statewide ... Nation. The campaign, launched by Nemours Health,and Prevention ... of,schools, communities, health professionals, parents, and other leaders ...
Cached Medicine News:Health News:Story Reveals How Isabel and Her Family Learn About Bone Health and Osteoporosis 2Health News:Story Reveals How Isabel and Her Family Learn About Bone Health and Osteoporosis 3Health News:St. Christopher's Foundation For Children Ronald McDonald(R) Care Mobile Making Tri-State Visits to Provide Dental Care to Children at No Cost 2Health News:RESolutions Rapid Enrollment Solutions, LLC Mobilizes Team of Regional Recruitment Specialists(TM) 2Health News:Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy 2Health News:Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy 3Health News:More than 125 State Leaders - Including Governor, Lt. Governor, and Congressional Delegation - Endorse Campaign to Make Delaware's Kids the Healthiest in the Nation 2Health News:More than 125 State Leaders - Including Governor, Lt. Governor, and Congressional Delegation - Endorse Campaign to Make Delaware's Kids the Healthiest in the Nation 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: